SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.
Investor's Business Daily on MSN8h
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?Moderna's technology focuses on helping the body create specific messenger RNA, or mRNA. When the mRNA sees ... Moderna sells ...
BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA ... PD-1 inhibitor Keytruda (pembrolizumab). mRNA-4157 is a personalised vaccine targeting 34 cancer neoantigens ...
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback